Advancements in
Artificial Intelligence (AI) Tools:
Focus on HER2 in Breast Cancer
On-Demand Webinar
Watch now by clicking below
This webinar will discuss and educate on:
Recognizing the changing landscape of HER2 testing and treatment, its impact on assessing HER2 IHC status in breast cancer, and specific challenges pathologists face in scoring HER2 expression.
Understanding of CISH (chromogenic in situ hybridization) and FISH (fluorescent in situ hybridization) methods for HER2 ISH testing in breast cancer, including the major differences and similarities in these methods, potential challenges to manual scoring, and potential utility for AI assistive tools in scoring.
Describing AI assistive tools for HER2 scoring and assessment in breast cancer, how the market is changing from our past to our current practices, and what we can look for in the future.
The Evolution of HER2 Testing and Treatment and Challenges in Manual Scoring of HER2 IHC
An overview of HER2 Chromogenic in-situ Hybridization (CISH) and FISH
The Role of AI tools in Determining HER2 Status in Breast Cancer
Slide Review of HER2 IHC and CISH with Image Analysis
Fill out the form below to be contacted by a Roche representative
Roche navify Digital Pathology, uPath Enterprise Software and Roche uPath HER2 Dual ISH Image Analysis for Breast are intended for research use only. Not for use in diagnostic procedures.
Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46256
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin. © 2024 Roche Diagnostics